Investors are optimistic about STERIS (STE) owing to its robust segmental results and the ongoing Cantel Medical integration.
With its stock down 18% over the past three months, it is easy to disregard STERIS (NYSE:STE). However, the company's...
Steris (STE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.